Phase I trial of Intraperitoneal (IP) administration of a measles virus (MV) derivative expressing the human carcinoembryonic antigen (CEA) in recurrent ovarian cancer (OvCa)

被引：4
|
作者：
Galanis, E. [1 ]
Hartmann, L. C. [1 ]
Cliby, W. [1 ]
Peethambaram, P. P. [1 ]
Long, H. J. [1 ]
Kaur, J. S. [1 ]
Haluska, P., Jr. [1 ]
Sloan, J. A. [1 ]
Peng, K. [1 ]
Russell, S. J. [1 ]
机构：
[1] Mayo Clin, Coll Med, Rochester, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.5538
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5538
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Intraoperative intraperitoneal (IP) chemotherapy with cisplatin and escalated dose of epinephrine in patient with recurrent peritoneal carcinomatosis of ovarian cancer: A phase I study
    Guardiola, E.
    Chauffert, B.
    Delroeux, D.
    Benoit, L.
    Causeret, S.
    Combe, M.
    Royer, B.
    Plaza, J.
    Heyd, B.
    Pivot, X.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [22] A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer
    Eder, JP
    Kantoff, PW
    Roper, K
    Xu, GX
    Bubley, GJ
    Boyden, J
    Gritz, L
    Mazzara, G
    Oh, WK
    Arlen, P
    Tsang, KY
    Panicali, D
    Schlom, J
    Kufe, DW
    CLINICAL CANCER RESEARCH, 2000, 6 (05) : 1632 - 1638
  • [23] A Phase I Trial of Vaccination with Carcinoembryonic Antigen (CEA) and Her2/neu (Her2) Peptides in Advanced Colorectal Cancer
    Lynch, Kevin T.
    Squeo, Gabriella C.
    Kane, William J.
    Meneveau, Max O.
    Olson, Walter C.
    Petroni, Gina
    Slingluff, Craig L., Jr.
    Foley, Eugene F.
    Friel, Charles M.
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2021, 233 (05) : S51 - S52
  • [24] A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer®) in recurrent ovarian cancer:: A Gynecologic Oncology Group study
    Armstrong, Deborah K.
    Fleming, Gini F.
    Markman, Maurie
    Bailey, Howard H.
    GYNECOLOGIC ONCOLOGY, 2006, 103 (02) : 391 - 396
  • [25] Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule
    Hörig, H
    Lee, DS
    Conkright, W
    Divito, J
    Hasson, H
    LaMare, M
    Rivera, A
    Park, D
    Tine, J
    Guito, K
    Tsang, KWY
    Schlom, J
    Kaufman, HL
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2000, 49 (09) : 504 - 514
  • [26] Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule
    Heidi Hörig
    David S. Lee
    William Conkright
    Joe Divito
    Henry Hasson
    Michelle LaMare
    Audrey Rivera
    David Park
    John Tine
    Ken Guito
    Kwong Wong-Yok Tsang
    Jeffrey Schlom
    Howard L. Kaufman
    Cancer Immunology, Immunotherapy, 2000, 49 : 504 - 514
  • [27] PRELIMINARY RESULTS - "A PHASE I TRIAL OF ONCOLYTIC MEASLES VIROTHERAPY IN MESOTHELIOMA" INVESTIGATING THE INTRAPLEURAL ADMINISTRATION OF THE MODIFIED VACCINE STRAIN MEASLES VIRUS (MV-NIS) TO PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA
    Peikert, Tobias
    Molina, Julian
    Aderca, Ileana
    Albelda, Stephen
    Carlson, Stephanie
    Lowe, Val
    Maldonado, Fabien
    Mandrekar, Sumithra
    Patel, Manish
    Roden, Anja
    Van Keulen, Virginia
    Kratzke, Robert
    Galanis, Evanthia
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S640 - S640
  • [28] Phase I clinical trial of autologous T-cells genetically engineered with a chimeric receptor to target the follicle-stimulating hormone receptor (FSHR) in recurrent ovarian cancer (OVCA)
    Wenham, Robert
    Davila, Marco
    Abate-Daga, Daniel
    Mcgettigan, Melissa
    Wang, Xuefeng
    Boyle, Theresa
    Garzone, Pam
    Dorman, Denise
    Conejo-Garcia, Jose
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_3) : A353 - A354
  • [29] Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma
    Dispenzieri, A.
    Tong, C.
    LaPlant, B.
    Lacy, M. Q.
    Laumann, K.
    Dingli, D.
    Zhou, Y.
    Federspiel, M. J.
    Gertz, M. A.
    Hayman, S.
    Buadi, F.
    O'Connor, M.
    Lowe, V. J.
    Peng, K-W
    Russell, S. J.
    LEUKEMIA, 2017, 31 (12) : 2791 - 2798
  • [30] Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma
    A Dispenzieri
    C Tong
    B LaPlant
    M Q Lacy
    K Laumann
    D Dingli
    Y Zhou
    M J Federspiel
    M A Gertz
    S Hayman
    F Buadi
    M O'Connor
    V J Lowe
    K-W Peng
    S J Russell
    Leukemia, 2017, 31 : 2791 - 2798
12345